Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

33.08 USD +0.11 (+0.33%)
Official Closing Price Updated: 7:42 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Bausch Health Companies Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistance In JAMA Ophthalmology
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that JAMA Ophthalmology has published 10-year results of the ongoing, multicenter,... 
From PR Newswire
Bausch Health Initiates VIRAZOLE® (Ribavirin for Inhalation Solution, USP) Clinical Study in Patients with COVID-19
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it has initiated a clinical trial program in Canada evaluating an investigational use of VIRAZOLE®... 
From PR Newswire
Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, due to the emerging public health impact of the COVID-19 pandemic and to protect the health and... 
From PR Newswire
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced topline results from a Phase 2 study evaluating an investigative soluble solid dispersion (SSD)... 
From PR Newswire
VRX Investor Alert: Kyros Law is Filing Legal Claims on Behalf of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) Investors
Kyros Law Offices is alerting investors of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) that it is filing legal claims against the company on behalf of investors. 
From PR Newswire
Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today outlined several initiatives the Company is taking to contribute to the fight against COVID-19 (coronavirus). 
From PR Newswire
Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $100 million through the prepayment of senior secured term loans,... 
From PR Newswire
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan
From GlobeNewswire News Releases
Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, due to market conditions, it has determined to not pursue the previously announced opportunistic... 
From PR Newswire
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order... 
From PR Newswire
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance
From PR Newswire
Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the launch of a new... 
From PR Newswire
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash... 
From PR Newswire
Bausch Health Announces Participation In Upcoming Investor Conferences
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in three investor conferences. 
From PR Newswire
Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today... 
From PR Newswire
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the... 
From PR Newswire
Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company... 
From PR Newswire
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2019 financial results on Wednesday, Feb. 19, 2020. Bausch Health will host a conference... 
From PR Newswire
Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina
From GlobeNewswire News Releases
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat... 
From PR Newswire
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of... 
From PR Newswire
Nicox’s Partner Secures Approval of VYZULTA in Mexico
From GlobeNewswire News Releases
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the U.S. launch of expanded parameters for Biotrue® ONEday for Astigmatism daily... 
From PR Newswire
Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 38th Annual J.P. Morgan Healthcare Conference... 
From PR Newswire
Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class... 
From PR Newswire
Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses,... 
From PR Newswire
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food... 
From PR Newswire
Bausch Health Announces Conditional Redemption Of Existing Senior Notes
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced that it issued today a conditional notice of redemption for $1.240 billion aggregate principal amount of the... 
From PR Newswire
Bausch Health Announces Pricing of Private Offering of Senior Notes
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $1,250,000,000 aggregate principal amount of... 
From PR Newswire
Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD) For Use In Cataract Surgery
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TXS: BHC), announced today that it has initiated a clinical trial evaluating the safety and efficacy of a new... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.